27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Despite a second quarter earnings beat from Pfizer Inc. (NYSE: PFE), Citi said investors are focusing on the potential breakup of the company by the year-end. But, Citi still views the breakup as "unlikely."
Citi, which has a Neutral rating and $37 price target on the stock, attributed Pfizer's earnings beat to lower than expected R&D and tax rate for the quarter.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
"The reaffirmation of full year guidance suggests this is a phasing rather than fundamental issue," analyst Andrew Baum wrote in a note.
As such, Baum continue to prefer Buy-rated Bristol-Myers Squibb Co (NYSE: BMY) and Eli Lilly and Co (NYSE: LLY) in the US.
Among the EU majors, the analyst prefer Buy-rated AstraZeneca plc (ADR) (NYSE: AZN), GlaxoSmithKline plc (ADR) (NYSE: GSK), Roche Holding Ltd. (ADR) (OTC: RHHBY) and Novo Nordisk A/S (ADR) (NYSE: NVO).
At time of writing, shares of Pfizer fell 2.17 percent to $36.50.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.